Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USP Building Risk Model To Assess Supply Chain Vulnerabilities And Anticipate Drug Shortages

Model Mines Reference Standards Data

Executive Summary

The USP is developing a risk model to assess whether pharmaceutical supply chains are strong or weak based on demand for reference standards.

You may also be interested in...



Hospitals Struggle To Supply COVID-19 Teams With The Medicines They Need

Vials arrive in fits and starts, often in wrong sizes, as allocation quotas, quality issues and difficulty anticipating surges wreak havoc in pharmaceutical supply chain.

China’s Global Pharma Supply Chain Operations Resuming In Wake Of Outbreak, USP Says

USP reference standard sales showed slow resumption of API manufacturing in China and less-than-expected API use in India.

Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others

Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”

Topics

UsernamePublicRestriction

Register

PS142739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel